UK firm Cantab Biopharmaceuticals Limited has received significant funding from Celtic Pharma Holdings to focus research on developing “biosuperiors” – next-generation biologics with superior health benefits.

Cantab, a biopharmaceutical company wholly owned by CP2 will use the new funding to target specific biosuperior opportunities in haematology through its own resources and through agreements to access innovative technology platforms from third parties.

The initial funding is approximately £5m over three years and is designed to allow Cantab to take its first biosuperior product all the way through to Phase I and II clinical trials, after which new partners may be sought.

In the longer term, Cantab aims to build a pipeline of biosuperior candidates with improved bioavailability, immunogenicity, pharmacokinetics and pharmacodynamics for other therapeutic areas, including infectious disease.